'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy

Journal of General Virology

Volumn 94, Issue PART 6, 2013, Pages 1259-1265

  Bucci, Cristina ^a   von Delft, Annette ^a   Christian, Annabel ^b   Flemming, Vicki M ^a   Harrison, Abby ^a   Halliday, John ^a   Collier, Jane ^b   Manganis, Chris ^b   Klenerman, Paul ^a,c   Irving, William ^d   Barnes, Eleanor ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^d NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HEALTH CARE QUALITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IL28B GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAPID VIROLOGICAL RESPONSE; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

EID: 84877985241     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.051052-0     Document Type: Article

References (29)

1. Bochud, P. Y., Bibert, S., Kutalik, Z., Patin, E., Guergnon, J., Nalpas, B., Goossens, N., Kuske, L., Müllhaupt, B. & other authors (2012). IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394.
2. De Nicola, S., Aghemo, A., Rumi, M. G., Galmozzi, E., Valenti, L., Soffredini, R., De Francesco, R., Prati, G. M., D'Ambrosio, R. & other authors (2012). Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 55, 336-342.
3. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Jr, Häussinger, D., Diago, M., Carosi, G. & other authors (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975-982.
4. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H. & other authors (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401.
5. Hayes, C. N., Kobayashi, M., Akuta, N., Suzuki, F., Kumada, H., Abe, H., Miki, D., Imamura, M., Ochi, H. & other authors (2011). HCV substitutions and IL28B polymorphisms on outcome of peginterferon plus ribavirin combination therapy. Gut 60, 261-267.
6. Health Protection Agency (2009). Hepatitis C in the UK: Annual Report 2009. London: Health Protection Agency Centre for Infections.
7. Hézode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J. P., Bourlière, M., Gharakhanian, S. & other authors (2009). Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360, 1839-1850.
8. Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G. & other authors (1995). Histological grading and staging of chronic hepatitis. J Hepatol 22, 696-699.
9. Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P. & other authors (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364, 2405-2416.
10. Kwo, P. Y., Lawitz, E. J., McCone, J., Schiff, E. R., Vierling, J. M., Pound, D., Davis, M. N., Galati, J. S., Gordon, S. C. & other authors (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705-716.
11. Labie, D. & Gilgenkrantz, H. (2010). [IL28 (interferon l3) gene polymorphisms and response to IFN-a treatment in patients infected with hepatitis virus C]. Med Sci (Paris) 26, 225-226 (in French).
12. Lindh, M., Lagging, M., Färkkilä, M., Langeland, N., Mørch, K., Nilsson, S., Norkrans, G., Pedersen, C., Buhl, M. R. & other authors (2011). Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 203, 1748-1752.
13. Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D. & other authors (2005). Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352, 2609-2617.
14. Mangia, A., Thompson, A. J., Santoro, R., Piazzolla, V., Tillmann, H. L., Patel, K., Shianna, K. V., Mottola, L., Petruzzellis, D. & other authors (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139, 821-827.
15. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. & Albrecht, J. K. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
16. McCarthy, J. J., Li, J. H., Thompson, A., Suchindran, S., Lao, X. Q., Patel, K., Tillmann, H. L., Muir, A. J. & McHutchison, J. G. (2010). Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138, 2307-2314.
17. McHutchison, J. G., Everson, G. T., Gordon, S. C., Jacobson, I. M., Sulkowski, M., Kauffman, R., McNair, L., Alam, J., Muir, A. J. & PROVE1 Study Team (2009). Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360, 1827-1838.
18. Moghaddam, A., Melum, E., Reinton, N., Ring-Larsen, H., Verbaan, H., Bjøro, K. & Dalgard, O. (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53, 746-754.
19. Montes-Cano, M. A., García-Lozano, J. R., Abad-Molina, C., Romero-Gómez, M., Barroso, N., Aguilar-Reina, J., Núñez-Roldán, A. & González-Escribano, M. F. (2010). Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52, 33-37.
20. Mosbruger, T. L., Duggal, P., Goedert, J. J., Kirk, G. D., Hoots, W. K., Tobler, L. H., Busch, M., Peters, M. G., Rosen, H. R. & other authors (2010). Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 201, 1371-1380.
21. Poordad, F., McCone, J., Jr, Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D. & other authors (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364, 1195-1206.
22. Rallón, N. I., Naggie, S., Benito, J. M., Medrano, J., Restrepo, C., Goldstein, D., Shianna, K. V., Vispo, E., Thompson, A. & other authors (2010). Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24, F23-F29.
23. Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E. & other authors (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345.
24. Scherzer, T. M., Stättermayer, A. F., Strasser, M., Laferl, H., Maieron, A., Stauber, R., Datz, C., Dulic-Lakovic, E., Steindl-Munda, P. & other authors (2011). Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology 54, 1518-1526.
25. Sherman, K. E., Flamm, S. L., Afdhal, N. H., Nelson, D. R., Sulkowski, M. S., Everson, G. T., Fried, M. W., Adler, M., Reesink, H. W. & other authors (2011). Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365, 1014-1024.
26. Smith, K. R., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M. L., Spengler, U., Bassendine, M., Matthews, G. & other authors (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 3, 57.
27. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J. & other authors (2009). IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 41, 1100-1104.
28. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K. & other authors (2009). Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat Genet 41, 1105-1109.
29. Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O'Huigin, C., Kidd, J., Kidd, K., Khakoo, S. I. & other authors (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801.